Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs

References

• Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27(1):2–12. doi:10.3978/j.issn.1000-9604.2015.01.0625717220
   PubMed Web of Science ®Google Scholar
• Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six Phase III randomized controlled trials. Int J Cancer. 2012;131(5):E822–9. doi:10.1002/ijc.2739622161771
   PubMed Web of Science ®Google Scholar
• Schuler M, Paz-Ares L, Sequist LV, et al. First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019;133:10–19. doi:10.1016/j.lungcan.2019.04.00631200814
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa191366231751012
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-325281468
   PubMed Web of Science ®Google Scholar
• Liu J, Sun Y, Liu X, et al. Efficiency of different treatment regimens combining anti-tumor and anti-inflammatory liposomes for metastatic breast cancer. AAPS PharmSciTech. 2020;21(7):259. doi:10.1208/s12249-020-01792-z32914285
   PubMed Web of Science ®Google Scholar
• Van Berckelaer C, Van Geyt M, Linders S, et al. A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer. Breast. 2020;53:212–220. doi:10.1016/j.breast.2020.08.00632890963
   PubMed Web of Science ®Google Scholar
• Wang H, Ding Y, Li N, et al. Prognostic value of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in stage IV advanced gastric cancer. Front Oncol. 2020;10:841. doi:10.3389/fonc.2020.0084132637353
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu G, Pan Y, Li Y. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–8349. doi:10.1111/jcmm.1509732603520
   PubMed Web of Science ®Google Scholar
• Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020;20(1):464. doi:10.1186/s12885-020-06953-832448185
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Kucuk A, et al. Low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy. Gastroenterol Res Pract. 2020;2020:5701949. doi:10.1155/2020/570194932802045
   PubMed Web of Science ®Google Scholar
• Sun L, Hu W, Liu M, et al. High systemic inflammation response index (SIRI) indicates poor outcome in gallbladder cancer patients with surgical resection: a single institution experience in China. Cancer Res Treat. 2020. doi:10.4143/crt.2020.303
   Web of Science ®Google Scholar
• Lin J, Chen L, Chen Q, et al. Prognostic value of preoperative systemic inflammation response index in patients with oral squamous cell carcinoma: propensity score-based analysis. Head Neck. 2020;42(11):3263–3274. doi:10.1002/hed.2637532681711
   PubMed Web of Science ®Google Scholar
• Chao B, Ju X, Zhang L, Xu X, Zhao Y. A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients. Front Oncol. 2020;10:766. doi:10.3389/fonc.2020.0076632477958
   PubMed Web of Science ®Google Scholar
• Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019;89(11):E507–E513. doi:10.1111/ans.1548031667974
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019;367:l5460. doi:10.1136/bmj.l546031591158
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc361124154716
   PubMed Web of Science ®Google Scholar
• Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 2020;24(5):2993–3021. doi:10.1111/jcmm.1493431989747
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.02520303878
   PubMed Web of Science ®Google Scholar
• Schiffmann LM, Fritsch M, Gebauer F, et al. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. Br J Cancer. 2019;120(1):69–78. doi:10.1038/s41416-018-0198-330377339
   PubMed Web of Science ®Google Scholar
• Sun GY, Wang SL, Song YW, et al. Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy. Int J Radiat Oncol Biol Phys. 2020;108(1):277–285. doi:10.1016/j.ijrobp.2020.02.63332147519
   PubMed Web of Science ®Google Scholar
• Cortese N, Carriero R, Laghi L, Mantovani A, Marchesi F. Prognostic significance of tumor-associated macrophages: past, present and future. Semin Immunol. 2020;48:101408. doi:10.1016/j.smim.2020.10140832943279
   PubMed Web of Science ®Google Scholar
• Zmigrodzka M, Witkowska-Pilaszewicz O, Winnicka A. Platelets extracellular vesicles as regulators of cancer progression-an updated perspective. Int J Mol Sci. 2020;21(15):5195. doi:10.3390/ijms21155195
   PubMed Web of Science ®Google Scholar
• Mazaki J, Katsumata K, Kasahara K, et al. Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis. BMC Cancer. 2020;20(1):922. doi:10.1186/s12885-020-07429-532977767
   PubMed Web of Science ®Google Scholar
• Huh G, Ryu JK, Chun JW, et al. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. BMC Cancer. 2020;20(1):907. doi:10.1186/s12885-020-07390-332967632
   PubMed Web of Science ®Google Scholar
• Corbeau I, Thezenas S, Maran-Gonzalez A, Colombo PE, Jacot W, Guiu S. Inflammatory blood markers as prognostic and predictive factors in early breast cancer patients receiving neoadjuvant chemotherapy. Cancers (Basel). 2020;12(9):2666. doi:10.3390/cancers12092666
   PubMed Web of Science ®Google Scholar
• Zager Y, Hoffman A, Dreznik Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: the prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios. Surg Oncol. 2020;35:321–327. doi:10.1016/j.suronc.2020.09.00232977104
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.3005727152949
   PubMed Web of Science ®Google Scholar
• Xu L, Yu S, Zhuang L, et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34954–34960. doi:10.18632/oncotarget.1686528430597
   PubMedGoogle Scholar
• Li S, Lan X, Gao H, et al. Systemic inflammation response index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. J Cancer Res Clin Oncol. 2017;143(12):2455–2468. doi:10.1007/s00432-017-2506-328828692
   PubMed Web of Science ®Google Scholar
• Chen Y, Jiang W, Xi D, et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. J Investig Med. 2019;67(3):691–698. doi:10.1136/jim-2018-000801
   PubMed Web of Science ®Google Scholar
• Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018;65:503–510. doi:10.1016/j.intimp.2018.10.00230408627
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Huang X, et al. The preoperative systemic inflammation response index (SIRI) independently predicts survival in postmenopausal women with breast cancer. Curr Probl Cancer. 2020;44(4):100560. doi:10.1016/j.currproblcancer.2020.10056032122667
   PubMed Web of Science ®Google Scholar
• Sun S, Qu Y, Wen F, Yu H. Initial neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with inoperable locally advanced non-small-cell lung cancer. Biomark Med. 2020;14(14):1341–1352. doi:10.2217/bmm-2019-058332808809
   PubMed Web of Science ®Google Scholar
• Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8(6):886–894. doi:10.21037/tlcr.2019.11.1632010567
   PubMed Web of Science ®Google Scholar